

## **Principio, Inc. Announces Licensing Agreement for Novel Molecular Imaging and Therapeutic Radiopharmaceuticals for the Treatment of Cancer with Johns Hopkins School of Medicine**

*ROCKVILLE, MD, Feb. 10, 2010 — Principio Inc., a privately held emerging company developing novel molecular imaging agents and therapeutic radiopharmaceuticals for the treatment of cancer, today announced that the Company has obtained an exclusive license to several technologies developed at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.*

The molecules include novel imaging and radiotherapeutic agents for Epstein Barr Virus (EBV) associated tumors and prostate cancer. The EBV technology, published in the October 2008 issue of the journal *Nature Medicine*, leverages a specific enzyme produced by the virus to allow for the imaging and therapy of the tumors caused by the virus, which include numerous lymphomas, stomach cancer, nasopharyngeal cancers, and most AIDS related lymphomas.

Under the terms of the agreement, the license gives Principio exclusive, worldwide rights to commercialize these much needed imaging agents and therapy. Further details of the agreement were not disclosed.

"We are extremely delighted to have obtained exclusive rights to these novel, revolutionary, and much needed imaging and radiotherapeutic molecules. We will move quickly to commercialize these much needed therapies for these devastating cancers," stated Joe Hernandez, Founder and CEO of Principio.

### **About Principio**

Principio is a privately held emerging company developing novel molecular imaging agents and therapeutic radiopharmaceuticals for the treatment of cancer. The Company's technology is expected to have broad applications in the imaging and treatment of cancer. Additional information is available at <http://www.principioinc.com>.

*This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Principio's mission to develop and commercialize novel molecular imaging and radiotherapy agents, Principio's ability to develop new technologies to conduct imaging and therapy of cancer. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Principio caution investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Principio's expectations that they will incur operating losses in the near future, the early stage of development of Principio's products and*

*technologies, uncertainties related to preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, Principio reliance on research collaborations, the actions of competitors and the development of competing technologies, potential patent infringement claims against Principio products, processes and technologies, Principio's ability to protect their patents and proprietary rights and uncertainties relating to commercialization rights.*

**CONTACT INFO:**

Principio Media Relations, +1-301-526-5197, or [info@principioinc.com](mailto:info@principioinc.com)

Website: [www.principioinc.com](http://www.principioinc.com)